Intellia Therapeutics had its Relative Strength (RS) Rating upgraded from 75 to 81 Thursday.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of other stocks on the major indexes.
Decades of market research reveals that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves.
While it's not currently an ideal time to jump in, see if the stock is able to establish and enter a buy zone in heavy trade.
Intellia Therapeutics showed 0% earnings growth last quarter. Revenue increased -43%. Keep an eye out for the company's next round of numbers on or around Jul. 31.
Intellia Therapeutics earns the No. 212 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Harmony Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
